



**Special Broadcast**

**September 8, 2023**

**WF-97116- REMEMBER**

**A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in  
Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment**

**FDAAA/CIRB Completed**

This communication serves to let you know that WF-97116 REMEMBER study was FDAAA/CIRB completed as of 8/29/2023. You may now close out this study at your site.

Please remember that you should keep all study documents for 5 years, after the date of completion above.

We appreciate all sites who participated in this important study. A primary outcomes paper for this study has been submitted for publication. Once published we will inform you and also provide a lay language summary that you can share with your patients who participated in this important study, if you choose to.

If there are any questions, please contact [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu): Attn: WF-97116

Wake NCORP Website: <https://wakencorp.phs.wakehealth.edu/>



A program of the National Cancer Institute  
of the National Institutes of Health

Copyright © 2023 Wake Forest NCORP Research Base. All rights reserved.  
You were added to this email list when you were rostered to the WAKE NCORP Research Base

**Our mailing address is:**

Wake Forest NCORP Research Base  
Medical Center Blvd  
Winston Salem, NC 27157-0001

[Add us to your address book](#)

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#).

